Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Benitec Biopharma Inc. (NASDAQ: BNTC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Benitec Biopharma to Participate in Upcoming Conferences in March